➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Harvard Business School
Mallinckrodt
AstraZeneca
Baxter
Moodys
McKesson

Last Updated: August 7, 2020

DrugPatentWatch Database Preview

NICORETTE (MINT) Drug Profile

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Which patents cover Nicorette (mint), and when can generic versions of Nicorette (mint) launch?

Nicorette (mint) is a drug marketed by Glaxosmithkline and is included in two NDAs.

The generic ingredient in NICORETTE (MINT) is nicotine polacrilex. There are thirty drug master file entries for this compound. Fifty suppliers are listed for this compound. Additional details are available on the nicotine polacrilex profile page.

US ANDA Litigation and Generic Entry Outlook for Nicorette (mint)

A generic version of NICORETTE (MINT) was approved as nicotine polacrilex by P AND L on March 15th, 1999.

  Start Trial

Summary for NICORETTE (MINT)
Drug patent expirations by year for NICORETTE (MINT)
Recent Clinical Trials for NICORETTE (MINT)

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
University of Wisconsin, MadisonPhase 4
National Cancer Institute (NCI)Phase 4
GlaxoSmithKlinePhase 1

See all NICORETTE (MINT) clinical trials

US Patents and Regulatory Information for NICORETTE (MINT)

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Glaxosmithkline NICORETTE (MINT) nicotine polacrilex GUM, CHEWING;BUCCAL 018612-003 Dec 23, 1998 OTC Yes No   Start Trial   Start Trial   Start Trial
Glaxosmithkline NICORETTE (MINT) nicotine polacrilex GUM, CHEWING;BUCCAL 020066-003 Dec 23, 1998 OTC Yes No   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Boehringer Ingelheim
McKesson
AstraZeneca
Express Scripts
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.